

PTAC Decisions

Meeting	D	Product name	Generic name	New Product	Decision Yes/No	Reason	Priority	Criteria cited	NII	i	ii	iii	iv	v	vi	vii	viii
1-Aug-02		ReVia 50mg tabs	naltrexone	No	Yes		Moderate	i,ii,iii,iv,vii,viii		1	1	1	1			1	1
1-Aug-02		Lumigac 0.03% e	bimatoprost	No	Yes		Low	i,iii,vi		1		1			1		
Nov-02		metronidazole gel	metronidazole	No	Yes		Moderate		1								
Nov-02		Lamisil 250mg tab	terbinafine	No	Yes		High	i,ii,iv,vi		1	1		1		1		
May-03		Aricept	donepezil	Yes	Deferred		Low										
May-03		Diovan/Co-Diovan	valsartan	Yes	No	No health benefit/cost			1								
May-03		Evista	raloxifene	Yes	Yes		High		1								
May-03		Fosamax	alendronate	No-access criteria					1								
Aug-03		Glivec	imatinib	No	Yes				1								
Aug-03		Ezetrol	ezetimibe	Yes	No	Funded via exceptional circs											
Aug-03		Diamicron MR 30	gliclazide	Yes	No	No health gain			1								
Aug-03		Visudyne 30mL in	verteporfin	Yes	No	Poor quality submission/cost			1								
Aug-03		Revisions to DCS list-multiple			N/A												
Aug-03		Aricept	donepezil	Yes	No	Queried submission/cost			1								
Aug-03		Pulmozyme	dornase alfa	No	No	Insufficient submission			1								
Aug-03		clindamycin 1%		No	No	Pending therapeutic category review			1								
Aug-03		Scopoderm TTS	scopolamine	No-access criteria	Yes				1								
Aug-03		Mabthera	rituximab	No-access criteria	Yes		moderate-high		1								
Nov-03		Atrovent 21mcg	ipratropium	No-new dosage	Yes		moderate-high		1								
Nov-03		Theratears	carboxymethylcell	Yes	No	Poor quality submission			1								
Nov-03		Arcoxia	etoricoxib	Yes	No	Clinical need met by other prods			1								
Nov-03		Enbrel	etanercept	No-access criteria	Yes				1								
Nov-03		Zinat	clindamycin/cefur	No-access criteria	No	Cost(cl)/no clinical benefit(cef)			1								
Nov-03		Various	lamivudine	No-access criteria	Yes				1								
Nov-03		Trileptal	oxcarbazepine	No-access criteria	No	Unapproved indic./paucity of data			1								
Nov-03		Various	selegiline	No-removal from PS	Retained on PS	No worsening of mortality			1								
Feb-04		Femara	letrozole	No-access criteria	Yes		Low		1								
Feb-04		Risperdal Depot	risperidone	No-new dosage form	Yes		High	i,ii,iii,iv,vi,vii,viii		1	1	1	1		1	1	1
Feb-04		Visudyne Photody	verteporfin	Yes-reapplication.	Deferred	Referred to PTAC Oph. Sub-com.											
Feb-04		ReVia	naltrexone	No-reapplication.	Yes				1								
Feb-04		Multiple-delisting f	various	No	Deferred	Subject to consultation											
Feb-04		Multiple Sclerosis	interferon alpha/beta		No	Insufficient new evidence			1								
Feb-04		Growth Hormone therapy(adults)			No	Inconclusive QALY data			1								
Feb-04		Growth Hormone therapy(children)			No	Insufficient/conflicting data			1								
Feb-04		Enzyme replacement-Fabry's			No	Inconclusive data			1								
Feb-04		Lipitor	atorvastatin	No-revised access	Yes				1								
Feb-04		Crestor	rosuvastatin	Yes	No	Safety issues/clinical need met			1								
Feb-04		Dilatrend	carvedilol	Yes	Deferred	Subject to PC cost-utility analysis			1								
Feb-04		HRT-cost utility analysis			No	Considered PC analysis reasonable			1								
Feb-04		Spiriva	tiotropium	No-reapplication	Yes		High		1								
Feb-04		Singulair	montelukast	Yes-reapplication.	Yes*	*For specific patient sub-sets only	High/moderate		1								
Aug-04		Zostrix	capsaicin	No-reapplication	Yes*	For specific patient sub-sets only	Moderate	ii,iii,iv			1	1	1				
Aug-04		Lantus	insulin glargine	Yes	Yes*	Referred to Diabetes sub-cmtee	Low	i,ii,iii,iv,vi,viii		1	1	1	1		1		1
Aug-04		Remicade	infliximab	Yes	No	Funding thru DHBs											
Aug-04		CellCept	mycophenolate	No-widened access	Yes*		Moderate	I,ii,iv,vi,viii		1	1		1		1		1
Aug-04		Ebixa	mementine	Yes	No	Held to be not cost-effective											
Aug-04		Oral Impact		No-reapplication	Yes*					1	1				1	1	1
Aug-04		Spiriva	tiotropium	Yes-reapplication	Yes*	Re-affirmed previous reco. to list	High	I,ii,iii,iv,vi		1	1	1	1		1		

May-06 Fabrazyme	agalsidase beta	Yes	No	Cost. Issue for PHARMAC		1												
May-06 Enbrel	etanercept	No	Yes		Moderate													
May-06 Remicade	infliximab	No	No	Hospital-only/impractical in community		1												
May-06 Aldara	imiquimod	No-new indication	Yes		Medium				iii,iv,v,vi,vii		1	1	1	1	1			
May-06 Micardis	telmisartan	Yes	Yes						iv,vi			1			1			
May-06 Suboxone	buprenorphine/hal	Yes	Deferred	Referred to Mental Health Subcommittee														
May-06 Visudyne Photody	verteporfin	Yes- reapplication	No	PS not appropriate funding mechanism														
Aug-06 Jadelle	levonorgestrel im	No-new dosage	Yes	Considered submission to be poor	Moderate				i,ii,iii,iv,v,vi,vii		1	1	1	1	1	1	1	1
Aug-06 Viread	tenofovir disoprox	Yes	Yes		Moderate				i,iii,iv		1		1	1				
Aug-06 Alimta	pemetrexed disod	Yes	No	Inadequate efficacy. Clinical need met														
Aug-06 Exjade	deferasirox	Yes	Yes		High				i,iii,iv		1		1	1				
Aug-06 Enbrel	etanercept	No	Yes		Medium				i,iii,iv		1		1	1				
Aug-06 Certican	everolimus	Yes	No	Place in therapy not clear														
Aug-06 Zithromax	azithromycin	No-access criteria	No	Unapproved use														
Aug-06	hypertonic saline	No-new indication	Yes		Medium-high													
Aug-06 Pulmozyme	dornase alfa	No-widened access	No	Insufficient evidence														
Aug-06 Durogesic	fentanyl patches	No-widened access	Deferred	Referred to Analgesic Subcommittee														
Aug-06 Herceptin	trastuzumab	No-widened access	No	Uncertainty over 12mth data/cost														
Aug-06 Growth hormone (adults)		No-widened access	Deferred	Referred to PTAC subcommittee														
Nov-06 Baraclude	entecavir	Yes	No	Place in therapy not clear														
Nov-06 Optimum Xceed	blood glucose me	No	Deferred	No objection/ referred to Diabetes subctee														
Nov-06 Accu-Chek	blood glucose me	No	Deferred	No objection/ referred to Diabetes subctee														
Nov-06 Flomaxtra	tamsulosin	No-new dosage	No	Insufficient data														
Nov-06 Enbrel	etanercept	No-new indication	No	High cost/uncertain access criteria														
Nov-06 Faslodex	fulvestrant	Yes	Yes		Low				i,iii,vi		1		1	1				
Nov-06 Spiriva	tiotropium	No-reapplication	Yes						i,ii,iii,iv,v		1	1	1	1	1			
Nov-06 Movicol	macrogol	Yes	Yes		Medium				i,iii,iv		1		1	1				
Nov-06 Caelyx	pegylated doxoruu	Yes	No	High cost/unfavourable toxicity														
Nov-06 Traclear	bosentan	Yes-reapplication	Yes	Affirmed previous listing/low pr.	Low													
Nov-06 Humira	adalimumab	No-widened access	Yes		Medium-high				i,iii,iv,vi		1		1	1				1
Nov-06 Humira	adalimumab	No-widened access	Deferred	Reco. PHARMAC fund a TNF inhibitor														
Nov-06 Plavix	clopidogrel	No-widened access	Yes		High				i,iii		1		1					
Nov-06 Herceptin	trastuzumab	CaTSOP	Yes	Affirmed CaTSOP recommendations	High				i,ii,iii,iv,vi,vii		1	1	1	1			1	1
Feb-07 Herceptin	trastuzumab	Early breast cancer	Yes	Re-affirmed CaTSOP recommendations	High													
Feb-07 MabThera	rituximab	No-widened access	Yes		Low-medium				i,iii,iv,vi		1		1	1				1
Feb-07 Lexapro	escitalopram	Yes-reapplication	No	Cost. Clinical need met														
Feb-07 Zeldox	ziprasidone	Yes-reapplication	Yes		High				i,ii,iii,iv,vii		1	1	1	1				1
Feb-07 Modavigil	modafinil	Yes-reapplication	Yes	Because of a small unmet health need	Low-medium				iii,iv				1	1				
Feb-07 Persantin LA	dipyridamole+ace	No-new dosage	No	Supporting evidence considered poor/cost														
Feb-07 Fosamax Plus	alendronate+chol	No-new dosage	Yes		Low				i		1							
Feb-07 Ritalin LA	methylphenidate	No-new dosage	Yes		Medium				i,ii,iii,iv,vii		1	1	1	1				1
Feb-07 Kaletra	lopinavir/ritonavir	No-new dosage	Yes		Medium				i,iii,iv,vi		1		1	1				1
Feb-07 Topimax	topiramate	No-widened access	Yes		Low				i,iii,iv		1		1	1				
Feb-07 Sutent	sunitinib	Yes	No	High cost v competitor/limited support data														
Feb-07 Certican	everolimus	Yes-reapplication	No	Place in therapy not clear														
Feb-07 Alimta	pemetrexed	Yes-reapplication	No	No additional efficacy														

Totals

70 40 17 43 42 9 25 15 13

Results:

Decisions taken 146

Deferred 11

Therefore 135 decisions taken over period Aug '02 - Feb '07

Of these no criteria were cited on 70 occasions